Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), Drug Type (Over-The-Counter Drugs, Prescription Drugs), Route Of Administration, Drug Formulation, Distribution Channel - Global Forecast 2025-2032
Description
The Anti-Obesity Therapeutics Market was valued at USD 10.79 billion in 2024 and is projected to grow to USD 11.69 billion in 2025, with a CAGR of 8.81%, reaching USD 21.21 billion by 2032.
An authoritative overview framing how clinical breakthroughs, payer dynamics, and patient expectations are reshaping the anti-obesity therapeutics ecosystem
The global clinical and commercial focus on obesity has entered a new era driven by breakthroughs in biology, intensifying payer engagement, and evolving patient expectations. Advances in pharmacotherapy and combination modalities have expanded the therapeutic toolkit available to clinicians, prompting a reappraisal of treatment pathways that historically emphasized lifestyle interventions and bariatric surgery. Consequently, stakeholders across industry, healthcare delivery, and policy are reorienting priorities to integrate novel agents alongside procedural options, while also addressing adherence, safety perceptions, and long-term outcomes.
As the field matures, the interplay between clinical evidence, regulatory decisions, and commercial access is shaping a more structured ecosystem. Trial designs now emphasize real-world effectiveness and comorbidity impacts, payers increasingly request outcomes-based contracting and value demonstration, and manufacturers are refining patient support programs to improve persistence. This introduction frames the executive summary that follows, offering context for the strategic shifts, segmentation intelligence, regional dynamics, competitive positioning, and recommended actions designed to help leaders navigate a rapidly transforming therapeutic landscape.
How pharmacologic innovation, digital support systems, and evolving payer frameworks are jointly revolutionizing treatment approaches and commercial models in obesity care
The landscape for obesity treatment is undergoing transformative shifts as novel pharmacologic modalities, integrated care models, and data-driven reimbursement strategies converge. GLP-1 receptor agonists and next-generation incretin combinations have reset clinical expectations by delivering clinically meaningful weight reductions and improvements in metabolic comorbidities, which in turn have prompted clinicians to reconsider earlier treatment initiation and combination approaches. Simultaneously, the maturation of digital therapeutics and remote monitoring has created opportunities to couple pharmacotherapy with scalable behavioral support, improving adherence and outcomes.
Regulatory authorities and payers are responding to these therapeutic advances with updated assessment frameworks that emphasize long-term outcomes and total cost of care. As a result, manufacturers are shifting from traditional product-centric commercialization to outcomes partnerships with health systems and payers. Supply chain strategies are also evolving: companies are investing in diversified manufacturing footprints and cold-chain capabilities to support parenteral therapies while reducing exposure to single-source risks. Finally, public awareness campaigns and changing clinical guidelines are driving patient demand, creating a broader pool of candidates for medical management. Taken together, these shifts are creating new commercial opportunities while placing a premium on evidence generation, cross-functional coordination, and agility in market access execution.
The cumulative effects of recent tariff shifts on supply chains, procurement strategies, and commercial access for anti-obesity therapeutic manufacturers and providers
Recent changes in trade policy and tariff structures have introduced additional layers of complexity for stakeholders involved in the manufacture, importation, and distribution of anti-obesity therapeutics. Tariff increases on certain pharmaceutical inputs and imported finished products have altered landed costs and prompted multinational manufacturers to reassess supply chains, sourcing strategies, and production footprints. In response, several companies have accelerated nearshoring initiatives and expanded domestic manufacturing partnerships to mitigate tariff exposure and stabilize delivery timelines.
These adjustments have had a ripple effect across procurement practices and contracting approaches. Contract negotiators are increasingly incorporating tariff pass-through clauses and supply disruption contingencies into purchasing agreements. At the same time, procurement teams are seeking greater visibility into multi-tier supplier networks to identify tariff-sensitive nodes and to evaluate total landed cost implications beyond unit price. For clinical operations and hospital systems, formulary committees have begun factoring supply chain stability and procurement risk into selection decisions, especially where parenteral therapies require specialized distribution.
To adapt, commercial leaders are prioritizing scenario planning that factors in variable tariff regimes and customs processes. This includes diversifying supplier bases, qualifying alternate manufacturing sites, and strengthening logistics partnerships that offer tariff-optimized routing and bonded warehousing. Importantly, these adaptations are prompting cross-functional collaboration between regulatory affairs, supply chain, and commercial teams to ensure uninterrupted patient access while preserving profitability and pricing flexibility.
A comprehensive segmentation synthesis revealing how treatment types, administration routes, formulations, and distribution channels dictate clinical use and commercial strategy
A nuanced segmentation framework illuminates where therapeutic, regulatory, and commercial levers hold the most influence across patient journeys and product lifecycles. Treatment type distinguishes between medications and procedural treatments, with medications encompassing a range of agents such as bupropion-naltrexone, liraglutide, orlistat, phentermine-topiramate, semaglutide, and tirzepatide, while procedural treatments include adjustable gastric banding, endoscopic sleeve gastroplasty, and gastric bypass surgery. This dichotomy underscores differing clinical decision drivers: pharmacotherapies are often selected for incremental risk-benefit balances and chronic management, whereas procedural options are reserved for patients meeting specific clinical thresholds or seeking durable anatomical interventions.
Further differentiation by drug type separates over-the-counter preparations from prescription-only therapies, shaping distribution, marketing, and patient support models. Route of administration creates operational and adherence considerations; oral administration includes capsules and tablets that favor convenience and broad outpatient uptake, whereas parenteral administration, which comprises intravenous and subcutaneous approaches, demands clinical settings or robust patient training and support for home administration. Drug formulation also plays a critical role, with liquid, semi-solid, and solid dosage forms influencing stability, delivery, and manufacturing complexity. Finally, distribution channel segmentation spans hospitals and clinics pharmacies, online pharmacies, and retail pharmacies, each presenting distinct procurement workflows, payer interactions, and patient access pathways. Together, these segmentation lenses guide targeted clinical development, differentiated value propositions, and channel-specific commercialization tactics.
Regional imperatives and variations in access, regulation, and commercialization that determine strategic prioritization across the Americas, Europe Middle East & Africa, and Asia-Pacific
Geographic dynamics materially shape access models, regulatory expectations, and commercial pathways in obesity therapeutics. In the Americas, robust private and public payer engagement, high-profile clinical adoption of novel agents, and substantial direct-to-patient demand are driving rapid commercial activity. Manufacturers in this region focus on payer evidence generation, outcomes-based contracting, and patient support infrastructures to ensure persistence and adherence in ambulatory settings. In contrast, the Europe, Middle East & Africa region presents a broad tapestry of reimbursement frameworks and regulatory pathways, where national health technology assessment processes and varying affordability thresholds influence launch sequencing and pricing strategies. Consequently, companies often adopt region-specific evidence plans and pricing strategies to address heterogenous access criteria.
The Asia-Pacific corridor is characterized by heterogeneous regulatory landscapes, diverse healthcare financing models, and rapidly expanding urban populations with rising obesity prevalence. Local manufacturing partnerships and tailored market entry plans that consider national reimbursement policies and channel preferences are common strategies for commercialization. Across all regions, capacity for cold-chain logistics, availability of specialist services for parenteral administration, and cultural attitudes toward medical versus surgical management of obesity affect uptake patterns. Thus, regional insights must inform prioritization of clinical programs, supply chain investments, and stakeholder engagement to optimize access and adoption globally.
How clinical differentiation, manufacturing readiness, and digital partnerships are defining competitive advantage and reshaping industry alliances in obesity therapeutics
Competitive dynamics within the anti-obesity therapeutic space reflect both rapid innovation and intensifying commercial execution. Leading pharmaceutical developers are expanding clinical programs to explore combination regimens, new indications, and long-term safety profiles that resonate with payers and clinicians seeking durable benefit. At the same time, a subset of companies is investing in manufacturing scale-up and cold-chain logistics to secure first-mover advantages for parenteral agents. Smaller biotechs and academic spinouts continue to contribute early-stage innovation, particularly in targets that modulate appetite, energy expenditure, or metabolic setpoints.
Partnerships between biopharma firms and technology providers are emerging as a competitive differentiator, enabling integrated care models that combine pharmacotherapy with digital behavioral interventions and remote monitoring. These alliances help address adherence challenges and generate real-world evidence that supports reimbursement dialogues. In parallel, contract research organizations and specialty pharmacies are adapting services to manage complex administration requirements and to deliver patient education and adherence support. As competition intensifies, companies that align clinical differentiation with robust payer evidence, operational readiness, and patient-centric support will be best positioned to convert scientific potential into sustainable clinical and commercial impact.
Actionable cross-functional steps that align evidence, manufacturing resilience, and payer partnerships to accelerate access and sustain commercial performance in obesity care
Industry leaders should pursue a set of coordinated actions that align clinical evidence generation, commercial access, and operational resilience to capture emerging opportunities. First, prioritize integrated evidence strategies that pair randomized trial outcomes with real-world effectiveness and health economic data to satisfy payers and clinicians. Second, invest in supply chain diversification and manufacturing flexibility to reduce exposure to trade policy volatility and to ensure continuity for parenteral and temperature-sensitive products. Third, develop robust patient support and digital engagement programs that enhance adherence and produce measurable outcomes that can be shared with payers and providers.
Moreover, pursue collaborative contracting models with payers and providers that emphasize outcomes, shared risk, and stepwise access pathways. Engage early with regulatory and reimbursement stakeholders across key geographies to align clinical development plans with coverage expectations. Finally, build cross-functional launch teams that embed operations, medical affairs, and commercial strategy to shorten time-to-access and to adapt rapidly to evolving clinical guidelines. Implementing these recommendations will require disciplined prioritization of resources, clear governance, and iterative measurement of performance against access and clinical uptake objectives.
A transparent, multi-source research approach combining clinical evidence, regulatory review, and expert validation to underpin operational and commercial insights
This research synthesizes peer-reviewed literature, regulatory documents, clinical trial registries, industry disclosures, and primary interviews with key stakeholders to produce actionable insights. Evidence appraisal prioritized randomized controlled trials, longitudinal observational studies, payer policy statements, and regulatory guidance documents to ensure the clinical and access conclusions reflect current standards and practice. Supplementary analyses incorporated manufacturing and supply chain intelligence derived from public filings, logistics provider reports, and subject-matter expert interviews to contextualize operational recommendations.
Throughout the research process, rigorous verification procedures were applied, including triangulation of primary and secondary sources, expert validation of clinical interpretations, and cross-checking of regulatory timelines. Where appropriate, scenario analysis was used to explore the implications of policy shifts and supply chain disruptions. The methodology emphasizes transparency in source selection and interpretative framing to enable decision-makers to understand assumptions and limitations, and to adapt insights to their specific organizational contexts.
Strategic synthesis explaining why coordinated evidence, supply chain, and patient engagement efforts will determine long-term success in obesity therapeutics
The convergence of potent pharmacologic agents, evolving reimbursement models, and heightened patient demand is redefining how obesity is managed clinically and commercialized strategically. Stakeholders who act decisively to align clinical development with payer evidence needs, fortify supply chains against policy-driven disruptions, and deploy patient-centric engagement models will capture disproportionate value. Conversely, organizations that rely solely on traditional commercialization playbooks risk losing ground as new entrants and partnership models shift the basis of competition.
In closing, the future of obesity therapeutics will be determined not only by scientific breakthroughs but by the ability of organizations to translate efficacy into accessible, sustainable care pathways. Executives should use the insights in this summary to inform near-term investments, partnership choices, and operational planning, while continuing to monitor clinical, regulatory, and commercial signals that will shape the next wave of therapeutic and care delivery innovation.
Note: PDF & Excel + Online Access - 1 Year
An authoritative overview framing how clinical breakthroughs, payer dynamics, and patient expectations are reshaping the anti-obesity therapeutics ecosystem
The global clinical and commercial focus on obesity has entered a new era driven by breakthroughs in biology, intensifying payer engagement, and evolving patient expectations. Advances in pharmacotherapy and combination modalities have expanded the therapeutic toolkit available to clinicians, prompting a reappraisal of treatment pathways that historically emphasized lifestyle interventions and bariatric surgery. Consequently, stakeholders across industry, healthcare delivery, and policy are reorienting priorities to integrate novel agents alongside procedural options, while also addressing adherence, safety perceptions, and long-term outcomes.
As the field matures, the interplay between clinical evidence, regulatory decisions, and commercial access is shaping a more structured ecosystem. Trial designs now emphasize real-world effectiveness and comorbidity impacts, payers increasingly request outcomes-based contracting and value demonstration, and manufacturers are refining patient support programs to improve persistence. This introduction frames the executive summary that follows, offering context for the strategic shifts, segmentation intelligence, regional dynamics, competitive positioning, and recommended actions designed to help leaders navigate a rapidly transforming therapeutic landscape.
How pharmacologic innovation, digital support systems, and evolving payer frameworks are jointly revolutionizing treatment approaches and commercial models in obesity care
The landscape for obesity treatment is undergoing transformative shifts as novel pharmacologic modalities, integrated care models, and data-driven reimbursement strategies converge. GLP-1 receptor agonists and next-generation incretin combinations have reset clinical expectations by delivering clinically meaningful weight reductions and improvements in metabolic comorbidities, which in turn have prompted clinicians to reconsider earlier treatment initiation and combination approaches. Simultaneously, the maturation of digital therapeutics and remote monitoring has created opportunities to couple pharmacotherapy with scalable behavioral support, improving adherence and outcomes.
Regulatory authorities and payers are responding to these therapeutic advances with updated assessment frameworks that emphasize long-term outcomes and total cost of care. As a result, manufacturers are shifting from traditional product-centric commercialization to outcomes partnerships with health systems and payers. Supply chain strategies are also evolving: companies are investing in diversified manufacturing footprints and cold-chain capabilities to support parenteral therapies while reducing exposure to single-source risks. Finally, public awareness campaigns and changing clinical guidelines are driving patient demand, creating a broader pool of candidates for medical management. Taken together, these shifts are creating new commercial opportunities while placing a premium on evidence generation, cross-functional coordination, and agility in market access execution.
The cumulative effects of recent tariff shifts on supply chains, procurement strategies, and commercial access for anti-obesity therapeutic manufacturers and providers
Recent changes in trade policy and tariff structures have introduced additional layers of complexity for stakeholders involved in the manufacture, importation, and distribution of anti-obesity therapeutics. Tariff increases on certain pharmaceutical inputs and imported finished products have altered landed costs and prompted multinational manufacturers to reassess supply chains, sourcing strategies, and production footprints. In response, several companies have accelerated nearshoring initiatives and expanded domestic manufacturing partnerships to mitigate tariff exposure and stabilize delivery timelines.
These adjustments have had a ripple effect across procurement practices and contracting approaches. Contract negotiators are increasingly incorporating tariff pass-through clauses and supply disruption contingencies into purchasing agreements. At the same time, procurement teams are seeking greater visibility into multi-tier supplier networks to identify tariff-sensitive nodes and to evaluate total landed cost implications beyond unit price. For clinical operations and hospital systems, formulary committees have begun factoring supply chain stability and procurement risk into selection decisions, especially where parenteral therapies require specialized distribution.
To adapt, commercial leaders are prioritizing scenario planning that factors in variable tariff regimes and customs processes. This includes diversifying supplier bases, qualifying alternate manufacturing sites, and strengthening logistics partnerships that offer tariff-optimized routing and bonded warehousing. Importantly, these adaptations are prompting cross-functional collaboration between regulatory affairs, supply chain, and commercial teams to ensure uninterrupted patient access while preserving profitability and pricing flexibility.
A comprehensive segmentation synthesis revealing how treatment types, administration routes, formulations, and distribution channels dictate clinical use and commercial strategy
A nuanced segmentation framework illuminates where therapeutic, regulatory, and commercial levers hold the most influence across patient journeys and product lifecycles. Treatment type distinguishes between medications and procedural treatments, with medications encompassing a range of agents such as bupropion-naltrexone, liraglutide, orlistat, phentermine-topiramate, semaglutide, and tirzepatide, while procedural treatments include adjustable gastric banding, endoscopic sleeve gastroplasty, and gastric bypass surgery. This dichotomy underscores differing clinical decision drivers: pharmacotherapies are often selected for incremental risk-benefit balances and chronic management, whereas procedural options are reserved for patients meeting specific clinical thresholds or seeking durable anatomical interventions.
Further differentiation by drug type separates over-the-counter preparations from prescription-only therapies, shaping distribution, marketing, and patient support models. Route of administration creates operational and adherence considerations; oral administration includes capsules and tablets that favor convenience and broad outpatient uptake, whereas parenteral administration, which comprises intravenous and subcutaneous approaches, demands clinical settings or robust patient training and support for home administration. Drug formulation also plays a critical role, with liquid, semi-solid, and solid dosage forms influencing stability, delivery, and manufacturing complexity. Finally, distribution channel segmentation spans hospitals and clinics pharmacies, online pharmacies, and retail pharmacies, each presenting distinct procurement workflows, payer interactions, and patient access pathways. Together, these segmentation lenses guide targeted clinical development, differentiated value propositions, and channel-specific commercialization tactics.
Regional imperatives and variations in access, regulation, and commercialization that determine strategic prioritization across the Americas, Europe Middle East & Africa, and Asia-Pacific
Geographic dynamics materially shape access models, regulatory expectations, and commercial pathways in obesity therapeutics. In the Americas, robust private and public payer engagement, high-profile clinical adoption of novel agents, and substantial direct-to-patient demand are driving rapid commercial activity. Manufacturers in this region focus on payer evidence generation, outcomes-based contracting, and patient support infrastructures to ensure persistence and adherence in ambulatory settings. In contrast, the Europe, Middle East & Africa region presents a broad tapestry of reimbursement frameworks and regulatory pathways, where national health technology assessment processes and varying affordability thresholds influence launch sequencing and pricing strategies. Consequently, companies often adopt region-specific evidence plans and pricing strategies to address heterogenous access criteria.
The Asia-Pacific corridor is characterized by heterogeneous regulatory landscapes, diverse healthcare financing models, and rapidly expanding urban populations with rising obesity prevalence. Local manufacturing partnerships and tailored market entry plans that consider national reimbursement policies and channel preferences are common strategies for commercialization. Across all regions, capacity for cold-chain logistics, availability of specialist services for parenteral administration, and cultural attitudes toward medical versus surgical management of obesity affect uptake patterns. Thus, regional insights must inform prioritization of clinical programs, supply chain investments, and stakeholder engagement to optimize access and adoption globally.
How clinical differentiation, manufacturing readiness, and digital partnerships are defining competitive advantage and reshaping industry alliances in obesity therapeutics
Competitive dynamics within the anti-obesity therapeutic space reflect both rapid innovation and intensifying commercial execution. Leading pharmaceutical developers are expanding clinical programs to explore combination regimens, new indications, and long-term safety profiles that resonate with payers and clinicians seeking durable benefit. At the same time, a subset of companies is investing in manufacturing scale-up and cold-chain logistics to secure first-mover advantages for parenteral agents. Smaller biotechs and academic spinouts continue to contribute early-stage innovation, particularly in targets that modulate appetite, energy expenditure, or metabolic setpoints.
Partnerships between biopharma firms and technology providers are emerging as a competitive differentiator, enabling integrated care models that combine pharmacotherapy with digital behavioral interventions and remote monitoring. These alliances help address adherence challenges and generate real-world evidence that supports reimbursement dialogues. In parallel, contract research organizations and specialty pharmacies are adapting services to manage complex administration requirements and to deliver patient education and adherence support. As competition intensifies, companies that align clinical differentiation with robust payer evidence, operational readiness, and patient-centric support will be best positioned to convert scientific potential into sustainable clinical and commercial impact.
Actionable cross-functional steps that align evidence, manufacturing resilience, and payer partnerships to accelerate access and sustain commercial performance in obesity care
Industry leaders should pursue a set of coordinated actions that align clinical evidence generation, commercial access, and operational resilience to capture emerging opportunities. First, prioritize integrated evidence strategies that pair randomized trial outcomes with real-world effectiveness and health economic data to satisfy payers and clinicians. Second, invest in supply chain diversification and manufacturing flexibility to reduce exposure to trade policy volatility and to ensure continuity for parenteral and temperature-sensitive products. Third, develop robust patient support and digital engagement programs that enhance adherence and produce measurable outcomes that can be shared with payers and providers.
Moreover, pursue collaborative contracting models with payers and providers that emphasize outcomes, shared risk, and stepwise access pathways. Engage early with regulatory and reimbursement stakeholders across key geographies to align clinical development plans with coverage expectations. Finally, build cross-functional launch teams that embed operations, medical affairs, and commercial strategy to shorten time-to-access and to adapt rapidly to evolving clinical guidelines. Implementing these recommendations will require disciplined prioritization of resources, clear governance, and iterative measurement of performance against access and clinical uptake objectives.
A transparent, multi-source research approach combining clinical evidence, regulatory review, and expert validation to underpin operational and commercial insights
This research synthesizes peer-reviewed literature, regulatory documents, clinical trial registries, industry disclosures, and primary interviews with key stakeholders to produce actionable insights. Evidence appraisal prioritized randomized controlled trials, longitudinal observational studies, payer policy statements, and regulatory guidance documents to ensure the clinical and access conclusions reflect current standards and practice. Supplementary analyses incorporated manufacturing and supply chain intelligence derived from public filings, logistics provider reports, and subject-matter expert interviews to contextualize operational recommendations.
Throughout the research process, rigorous verification procedures were applied, including triangulation of primary and secondary sources, expert validation of clinical interpretations, and cross-checking of regulatory timelines. Where appropriate, scenario analysis was used to explore the implications of policy shifts and supply chain disruptions. The methodology emphasizes transparency in source selection and interpretative framing to enable decision-makers to understand assumptions and limitations, and to adapt insights to their specific organizational contexts.
Strategic synthesis explaining why coordinated evidence, supply chain, and patient engagement efforts will determine long-term success in obesity therapeutics
The convergence of potent pharmacologic agents, evolving reimbursement models, and heightened patient demand is redefining how obesity is managed clinically and commercialized strategically. Stakeholders who act decisively to align clinical development with payer evidence needs, fortify supply chains against policy-driven disruptions, and deploy patient-centric engagement models will capture disproportionate value. Conversely, organizations that rely solely on traditional commercialization playbooks risk losing ground as new entrants and partnership models shift the basis of competition.
In closing, the future of obesity therapeutics will be determined not only by scientific breakthroughs but by the ability of organizations to translate efficacy into accessible, sustainable care pathways. Executives should use the insights in this summary to inform near-term investments, partnership choices, and operational planning, while continuing to monitor clinical, regulatory, and commercial signals that will shape the next wave of therapeutic and care delivery innovation.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Surge in GLP-1 receptor agonist approvals for chronic weight management in diverse populations
- 5.2. Rising investment in oral small molecule candidates targeting appetite regulatory pathways
- 5.3. Expansion of combination therapies pairing GLP-1 analogs with SGLT2 inhibitors for enhanced efficacy
- 5.4. Integration of digital therapeutics and remote monitoring to support patient weight loss adherence
- 5.5. Growing emphasis on gut microbiome modulation through prebiotic and postbiotic formulations in obesity
- 5.6. Development of peptide-based weight loss drugs with improved oral bioavailability and safety profiles
- 5.7. Regulatory pathways evolving to accommodate accelerated approval of novel obesity therapies based on surrogate endpoints
- 5.8. Emergence of personalized nutraceuticals targeting genetic predispositions to obesity and metabolic syndrome
- 5.9. Collaboration between pharmaceutical and tech startups to develop AI driven obesity treatment decision support tools
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Anti-Obesity Therapeutics Market, by Treatment Type
- 8.1. Medications
- 8.1.1. Bupropion-Naltrexone
- 8.1.2. Liraglutide
- 8.1.3. Orlistat
- 8.1.4. Phentermine-Topiramate
- 8.1.5. Semaglutide
- 8.1.6. Tilzepatide
- 8.2. Treatments
- 8.2.1. Adjustable Gastric Banding
- 8.2.2. Endoscopic Sleeve Gastroplasty
- 8.2.3. Gastric Bypass Surgery
- 9. Anti-Obesity Therapeutics Market, by Drug Type
- 9.1. Over-The-Counter Drugs
- 9.2. Prescription Drugs
- 10. Anti-Obesity Therapeutics Market, by Route Of Administration
- 10.1. Oral Administration
- 10.1.1. Capsules
- 10.1.2. Tablets
- 10.2. Parenteral Administration
- 10.2.1. Intravenous
- 10.2.2. Subcutaneous
- 11. Anti-Obesity Therapeutics Market, by Drug Formulation
- 11.1. Liquid Dosage Forms
- 11.2. Semi-Solid Dosage Forms
- 11.3. Solid Dosage Forms
- 12. Anti-Obesity Therapeutics Market, by Distribution Channel
- 12.1. Hospitals & Clinics Pharmacies
- 12.2. Online Pharmacies
- 12.3. Retail Pharmacies
- 13. Anti-Obesity Therapeutics Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Anti-Obesity Therapeutics Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Anti-Obesity Therapeutics Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Alizyme PLC
- 16.3.2. Amgen Inc.
- 16.3.3. Arena Pharmaceuticals Inc.
- 16.3.4. Boehringer Ingelheim International GmbH
- 16.3.5. Bristol-Myers Squibb Company
- 16.3.6. Currax Pharmaceuticals LLC
- 16.3.7. Eisai Co. Ltd.
- 16.3.8. Eli Lilly and Company
- 16.3.9. F. Hoffmann-La Roche Ltd
- 16.3.10. FlaxoSithKline plc.
- 16.3.11. GlaxoSmithKline PLC
- 16.3.12. Johnson & Johnson Services Inc.
- 16.3.13. Merck & Co. Inc.
- 16.3.14. Nalpropion Pharmaceuticals Inc.
- 16.3.15. Norgine B.V.
- 16.3.16. Novartis AG
- 16.3.17. Novo Nordisk A/S
- 16.3.18. Orexigen Therapeutics Inc.
- 16.3.19. Pfizer Inc.
- 16.3.20. Rhythm Pharmaceuticals, Inc.
- 16.3.21. Sanofi S.A.
- 16.3.22. SHIONOGI & Co., Ltd.
- 16.3.23. Takeda Pharmaceutical Company Limited
- 16.3.24. Vivus Inc.
- 16.3.25. Zydus Lifesciences Limited
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
